CapVest, a London-based private equity firm managing €7bn in assets, closed the acquisition of Stada Arzneimittel AG for €5.3 billion including debt, marking Europe's largest leveraged buyout in 2025. The transaction unseated deals from Blackstone and KKR, neither of which completed a European LBO above €4bn this calendar year.
The firm outbid three larger competitors in a fourth-quarter auction process managed by Goldman Sachs. Stada, a generic pharmaceutical manufacturer with €3.6bn in trailing revenue and operations across 30 European markets, had been held by Bain Capital and Cinven since 2017. Those sponsors acquired the business for €4.3bn and are exiting at a 1.6x gross multiple over eight years. CapVest funded the purchase with €2.1bn in equity, €2.8bn in senior debt from Deutsche Bank and BNP Paribas, and €400m in preferred equity from a single Canadian pension fund.
The deal matters because it demonstrates two structural shifts in European buyouts. First, regional firms with sector-specific operational playbooks are now competing successfully against multi-strategy giants on headline transactions. CapVest has spent 18 months building a pharmaceutical operating team led by former Teva executives, a capability Blackstone does not replicate in its European office. Second, the financing market has reopened for pharma assets with predictable cash flows. Stada's covenant-lite senior debt priced at EURIBOR plus 375 basis points, inside the 400-450bp range that prevailed for similar credits in 2023. That spread compression added €80m in annual interest savings, which funded a portion of CapVest's return case without operational improvement.
Allocators should note that CapVest's next fund, Fund VI, is currently in market targeting €3bn and is likely to close above €3.5bn on the strength of this result. The firm has told LPs it will focus exclusively on European healthcare and consumer businesses with €500m to €5bn enterprise values. That positioning directly competes with the lower end of EQT's buyout strategy and the upper end of Astorg's range. The Stada acquisition also validates a financing structure that could be repeated: Canadian pensions and sovereign wealth funds are now willing to provide €300m to €500m preferred equity checks at 10-12% yields to replace mezzanine debt, which effectively disappeared from the European market in 2023.
Watch for two follow-on events in the next 90 days. CapVest will announce an operational plan for Stada that likely includes a carve-out of its Eastern European retail pharmacy chain, which generates €600m in revenue but operates at half the margin of the core generics business. The Canadian pension fund that provided preferred equity, believed to be OMERS or CPPIB, may also announce a co-investment vehicle targeting similar structures in European pharma and medtech, which would create a new institutional buyer category for assets in the €1bn to €3bn range.